1. Amyloidosis Research and Treatment Centre, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy;
2. Amyloidosis Center, Boston Medical Center, Boston, MA, USA;
3. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico;
4. Hospital de Santo António, Centro Hospitalar do Porto, Porto, Portugal;
5. Division of Medicine, National Amyloidosis Centre, University College London, London, UK;
6. Medical Clinic for Gastroenterology and Hepatology, University of Münster, Münster, Germany;
7. Department of Neurology, Institute of Translational Neurology, University Hospital Münster, Münster, Germany;
8. Department of Neurology, Kumamoto University, Kumamoto, Japan;
9. Assistance Publique–Hôpitaux de Paris (APHP), French National Reference Center for Familial Amyloidotic Polyneuropathy, Centre Hospitalier Universitaire Bicêtre, Universite Paris-Sud, INSERM Unite, Paris, France;
10. Department of Neurology, Columbia University Medical Center, New York, NY, USA;
11. Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA;
12. Department of Medicine, Mount Sinai Medical Center, New York, NY, USA;
13. Department of Cardiology, University of Heidelberg, Heidelberg, Germany;
14. Alnylam Pharmaceuticals, Cambridge, MA, USA